A lot of folks on this board have explored or taken treatment with the Plexxikon BRAF inhibitor (also known as PLX4032). The various companies involved in developing that drug announced early this morning that they have submitted the drug for approval by the FDA. They are now calling it "vemurafenib."
If they submitted under acclerated approval (which I think they did) the FDA decision should come within the next six months, and possibly sooner.
A lot of folks on this board have explored or taken treatment with the Plexxikon BRAF inhibitor (also known as PLX4032). The various companies involved in developing that drug announced early this morning that they have submitted the drug for approval by the FDA. They are now calling it "vemurafenib."
If they submitted under acclerated approval (which I think they did) the FDA decision should come within the next six months, and possibly sooner.
Yervoy was approved in March this year. If vemurafenib is approved this year, that will mean two new drugs in one year–after 13 years of no new drugs being approved.
Neither of these drugs is what anyone would call a home run, but it is good to see some movement after many years of dissapointment.
Tim–MRF
.
.
